Novel D-Enantiomeric Peptides Derived from D3 and Use Thereof

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes new D-enantiomeric (mirror-image) peptides derived from the D3 peptide, which can selectively bind to amyloid-beta oligomers—aggregated proteins found in the brains of Alzheimer's Disease patients. These peptides, or their fragments and polymers, are capable of inhibiting the formation of harmful aggregates, neutralizing toxic oligomers, and can be used as probes for the early diagnosis or as therapeutic agents in Alzheimer's disease.

Use CasesContent extracted from patent full text and abstract with AI.

• Preventing or treating Alzheimer's Disease by inhibiting amyloid-beta aggregation.
• Neutralizing and detoxifying toxic amyloid-beta oligomers in the brain.
• Development of imaging probes for early diagnosis of Alzheimer's Disease through detection of amyloid-beta aggregates.
• In vitro or ex vivo removal or neutralization of amyloid-beta oligomers from blood, blood products, or organs.
• Formulation of new Alzheimer's drugs, vaccines, or supplements containing the D-enantiomeric peptides.
• Use as molecular probes in imaging procedures like PET, MRI, or CT for research and clinical diagnostics.

BenefitsContent extracted from patent full text and abstract with AI.

• Improved specificity and affinity for toxic amyloid-beta oligomers compared to previous peptides.
• Potential for early intervention in Alzheimer's Disease before significant symptoms develop.
• Enhanced resistance to degradation due to D-amino acid composition, leading to longer-lasting therapeutic or diagnostic agents.
• Reduced risk of immune reactions thanks to non-natural chirality.
• Versatility in formulation—as drugs, vaccines, diagnostic kits, imaging probes, or supplements.
• Ability to both prevent and treat disease by inhibiting aggregation and neutralizing already formed toxic species.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to novel D-enantiomeric A-beta-oligomer-binding peptides, homologs, fragments, parts and polymers thereof and the use thereof.